Inhibition of 5-Lipoxygenase Pathway Attenuates Acute Liver Failure by Inhibiting Macrophage Activation

Lu Li, Yi-Rong Liu, Shan Gao, Jun-Feng Li, Shan-Shan Li, Dan-Dan Zhang, Shuang Liu, Li Bai, Su-Jun Zheng, Zhong-Ping Duan, Min Qi, and Yu Chen

1. Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
2. Department of Toxic Hepatic Diseases, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
3. Department of General Medicine, Luoyang Central Hospital, Zhengzhou University, Luoyang 471000, China

Correspondence should be addressed to Min Qi; qimin19720629@163.com and Yu Chen; chybeyond@163.com

Received 15 March 2014; Accepted 12 May 2014; Published 1 June 2014

1. Introduction

Acute liver failure (ALF), characterized by massive necrosis, is a syndrome defined by the onset of coagulopathy and hepatic encephalopathy and has a mortality rate ranging from 50% to 70% [1–6]. The prognosis of this disease has not significantly improved, despite the introduction of supporting treatments such as plasma exchange, dialysis, and antibiotics [7–10]. Although liver transplantation is an effective treatment, it is not universally applicable. With the limited understanding of the pathogenesis, no effective therapy is available to prevent or treat this disease.

Recently, several authors have reported the increased serum levels of macrophage-derived factors in patients with ALF, irrespective of the trigger, which suggests that activated macrophages play an important role in the progression of ALF [11–13]. Indeed, activation of macrophages and the subsequent release of proinflammatory mediators such as cytokines (e.g., tumor necrosis factor (TNF)-α), reactive oxygen species (ROS), and eicosanoids are considered to be an early step in the pathogenesis of liver damage, because they stimulate hepatic inflammation. Moreover, in the animal model of liver disease, the number of macrophages increases consistently and correlates closely with the degree of hepatic injury [14]. Thus, selective inactivation of macrophages might be a potential approach for the treatment of ALF.

In the liver, macrophages are the only cell type endowed with a metabolically active 5-lipoxygenase (5-LO) pathway (i.e., 5-LO, 5-LO-activating protein (FLAP), leukotriene (LT) C4 synthase, and generated LTB4 and cysteinyl-LT1s), which is
necessary for the biosynthesis of LTs [15]. LTs are metabolites of the 5-LO pathway and have been shown to enhance injury to organs during endotoxemia. In addition, LTB4 is a chemoattractant for leukocytes and plays a pivotal role in the pathogenesis of inflammatory and immune diseases [16]. Thus, the 5-LO pathway leading to the production of LTs is a major proinflammatory pathway in macrophages.

The expression of 5-LO in the liver is restricted to macrophages and 5-LO is necessary for the progression of ALF. We hypothesize that the mechanism of blocking the 5-LO pathway protects the liver from necroinflammatory damage and may be related to inhibiting activation of macrophages. Therefore, 5-LO inhibitors may have a therapeutic effect on ALF by inhibiting macrophage activation. Using AA-861 as a specific 5-LO inhibitor, the present study investigated the role of 5-LO in ALF in rats and changes in activation of macrophages by blocking it.

2. Materials and Methods

2.1. Experimental Animals. Male Wistar rats (weighing 150–180 g) were obtained from the Academy of Military Medical Sciences, China. They were acclimatized to animal house conditions and were fed a standard pellet diet and water ad libitum for 1 week. The experiments were conducted according to the ethical norms approved by the Ministry of Social Justices and Empowerment, China, and Institutional Animal Ethics Committee guidelines. This study was also approved by Ethics Committee of Beijing YouAn Hospital (Review number 2012-58).

2.2. Main Chemicals. D-Galactosamine (D-GalN), lipopolysaccharide (LPS), AA-861, dimethyl sulfoxide (DMSO), Tween, and phenylmethylsulfonyl fluoride (PMSF) were purchased from Sigma (St. Louis, MO, USA). Dulbecco-Vogt phosphate-buffered saline (DPBS), LTB4 Elisa kit, and Sep-Pak C18 cartridges were obtained from Cayman Chemical Co. (Ann Arbor, MI, USA). β-Mercaptoethanol, tetramethylthelylenediamine (TEMED), and diethylpyrocarbonate (DEPC) were purchased from Amresco Biochemical Co. (Solon, OH, USA). RIPA and TRIzol RNA were purchased from Invitrogen (Carlsbad, CA, USA). The microbicin-choninic acid (BCA) protein assay reagent kit was from Pierce (Rockford, IL, USA). Immobilon-P transfer membranes were from Millipore (Bedford, MA, USA). Mouse anti-rat monoclonal ED1 antibody and rabbit anti-rat polyclonal 5-LO antibody were provided by Abcam (Cambridge, MA, USA). Rabbit anti-rat monoclonal β-actin antibody was purchased from Epitomics (Burlingame, CA, USA). TNF-α Elisa kit was provided by IBL (Minneapolis, MN, USA). The SuperScript II Reverse Transcriptase Kit, TaqMan Gene Expression Assay, and universal TaqMan 2x polymerase chain reaction (PCR) master mix were from Takara Bio (Dalian, China).

2.3. Animal Model. Seventy-six male Wistar rats were randomly divided into three groups. (1) Control group (6 rats): DMSO (1.5 mL) was injected intraperitoneally. After 12 hr, the rats were fasted for a further 12 hr and 0.9% NaCl (2 mL) was injected intraperitoneally. Twenty-four hours after saline injection, the rats were killed and the liver tissues and serum were collected for further analysis. (2) ALF group (35 rats): DMSO (1.5 mL) was injected intraperitoneally. After 12 hr, the rats were fasted for a further 12 hr and D-GalN/LPS (1200 mg/kg D-GalN, 100 µg/kg LPS) was injected intraperitoneally. Six rats were killed randomly 8 and 24 hr, respectively, after D-GalN/LPS administration and the liver tissue and serum were collected for further analysis. (3) AA-861 prophylactic group (35 rats): AA-861 (60 mg/kg) was injected intraperitoneally 12 hr later, the rats were fasted for a further 12 hr, and D-GalN/LPS (1200 mg/kg D-GalN, 100 µg/kg LPS) was administrated intraperitoneally. Six rats were killed randomly after 8 and 24 hr, respectively, after D-GalN/LPS administration and the liver tissue and serum were collected for further analysis. Twenty rats in groups 2 and 3 were housed for further survival observation.

2.4. Biological Assays. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (Tbil) levels were measured with an autoanalyzer (AU 5400; Olympus Optical Co., Japan).

2.5. Histological Analysis. Liver samples were cut into 5-mm sections, fixed in 4% formaldehyde and embedded in paraffin, and stained with hematoxylin and eosin for histological analysis. Hepatocellular necrosis was assessed by a registered pathologist who was unaware of the treatments. Parts of Modified Histological Activity Index were performed to evaluate the necroinflammatory degree (confluent necrosis score and spotty lytic necrosis, apoptosis, and focal inflammation score).

2.6. Transmission Electron Microscopy of Macrophages. Liver samples were cut into 1-mm sections and fixed in 2.5% glutaraldehyde with 2% paraformaldehyde for 2 hr at 4°C. The liver samples were washed three times for 10 min each with sodium dimethyl arsenic acid buffer (pH 7.2) and fixed in 1% osmic acid for 2 hr at 4°C. Two hours later, tissues were washed three times for 10 min each with double-distilled water. The samples were dehydrated through an ethanol gradient (50%, 70%, and 90%, 10 min each), anhydrous alcohol, and epoxy propylene twice for 15 min each. After the metathesis step, liver samples were embedded in pure phenolic resin. Polymerization conditions were 30°C (5 hr), 50°C (5 hr), and 80°C (5 hr). Semithin sections were cut and stained with uranyl acetate and lead citrate. The sections were observed under a transmission electron microscope (H-7650, Hitachi, Japan).

2.7. 5-LO and Macrophages Quantified by Immunohistochemistry. ED1-positive or 5-LO-positive cells were detected immunohistochemically by the avidin-biotin complex method using a Vectastain elite ABC kit as described previously [17], with modifications. Liver sections were deparaffinized and incubated with preheated (37°C) 0.1%
Figure 1: 5-LO specific inhibitor AA-861 prevented hepatocellular necrosis in D-GalN/LPS-treated rats. Representative photomicrographs of liver sections stained with hematoxylin and eosin from the control group receiving placebo (left panels), 24 hr D-GalN/LPS-treated rats receiving placebo (middle panels), and 24 hr D-GalN/LPS-treated rats receiving AA-861 (right panels). Confluent necrosis score and spotty lytic necrosis, apoptosis, and focal inflammation score in Modified Histological Activity Index system were employed. Control: 0; D-GalN/LPS: 9; AA-861 + D-GalN/LPS: 2.
5-LO specific inhibitor AA-861 decreased levels of serum ALT, AST, and Tbil in D-GaIN/LPS-treated rats. ((a)–(c)) Compared with experimental groups, the levels of serum ALT, AST, and Tbil in the AA-861 treatment groups were significantly decreased 8 and 24 hr after induction of ALF (P < 0.05).

Figure 2: 5-LO specific inhibitor AA-861 decreased levels of serum ALT, AST, and Tbil in D-GaIN/LPS-treated rats. ((a)–(c)) Compared with experimental groups, the levels of serum ALT, AST, and Tbil in the AA-861 treatment groups were significantly decreased 8 and 24 hr after induction of ALF (P < 0.05).

trypsin solution for 15 min and then with 3% H$_2$O$_2$ for 10 min to quench endogenous peroxidase. To block nonspecific reactions, sections were incubated with goat blocking serum for 30 min and then with avidin-biotin blocking solution according to the manufacturer’s instructions. Following blocking, sections were incubated overnight at 4°C with mouse anti-rat monoclonal ED1 antibody (1:150) or rabbit anti-rat polyclonal 5-LO antibody (1:100) as the primary antibody and then incubated for 30 min with a biotinylated goat anti-mouse antibody or a biotinylated goat anti-rabbit antibody. Sections were incubated for 30 min with the avidin-horseradish peroxidase (HRP) complex, then treated with DAB (3,3′-Diaminobenzidine Tetrahydrochloride) Horseradish Peroxidase Color Development Kit for 5 min, and finally counterstained with hematoxylin. Sections were dehydrated, cleared, and mounted in VectaMount mounting medium. For quantitative analysis, the number of ED1-positive or 5-LO-positive cells was counted in a total of 25 high-power fields (HPFs) per tissue section under a light microscope (BH-2; Olympus Optical Co., Japan) at 100, 200, and 400x magnification, and results were presented as number of positive cells/HPF.

2.8. LTB4 in Liver Tissue and TNF-α in Serum. Liver tissue (120 mg) was homogenized with an Ultra-Turrax basic homogenizer (Biospec, Bartlesville, OK, USA) in 4 mL DPBS and kept with 2 vol. ice-cold methanol. Homogenates were centrifuged at 2000 rpm for 10 min at 4°C, and eicosanoids present in the supernatants were extracted with Sep-Pak C18 cartridges. The eluted methyl formate and methanol fractions were taken for further analysis of LTB4 levels, by specific enzyme immunoassay kit [14].

Blood collected from the inferior vena cava was centrifuged at 1500 rpm for 10 min, and the supernatant was used for TNF-α analysis.

2.9. 5-LO mRNA Transcription. Total RNA (2.5 μg) was isolated from rat liver tissue and reverse-transcribed into cDNA with the SuperScript III First-Strand Synthesis System
(Invitrogen). The RT reaction mixture (in a final reaction volume of 20 μL) contained the following: 10 μL 1x SuperMix (SYBR Premix Ex Taq; Takara), 2 μL cDNA, 0.4 μL 50x Rox Reference Dye I, 6.8 μL dH₂O₂, and 0.4 μL each primer. Real-time quantitative PCR was performed with an ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). 5-LO primer sequence is as follows: forward: 5'-ACGTTTTAGGCATGCGGCGGCG-3'; reverse: 5'-ATTGGGCTCGGCAATCAGCG-3', using β-actin as an endogenous control. Amplification conditions were 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. PCR results were analyzed with the sequence detector software version 2.1 (Applied Biosystems). A relative quantitation of gene expression was calculated using the standard curve method.

2.10. Total 5-LO Protein Quantification by Western Blotting. Liver tissue stored at –80°C was homogenized in 8 vol. 10 mM HEPES/KOH, pH 7.4, containing 0.25% (w/v) sucrose, 2 mM EDTA, aprotinin (1 μg/mL), leupeptin (1 μg/mL), pepstatin A (1 μg/mL), and 10 μM PMSF. After centrifugation at 1200 rpm for 15 min at 4°C, the supernatant was collected and the protein concentration was measured spectrophotometrically using the BCA method (protein assay) following the Pierce Co's protocol. Western blot analysis for 5-LO was performed as described previously [18]. Total protein (160 μg) was subjected to 12% SDS-PAGE and transferred to PVDF nitrocellulose membranes. Antibodies against phosphorylated and total 5-LO, as well as β-actin, were used for western blot analysis. Membranes were probed with primary antibody (1:750) in 10 mL blocking buffer overnight at 4°C. After washing, membranes were further probed with appropriate HRP-conjugated secondary antibody (1:3000) in 10 mL blocking buffer for 1 h at room temperature. SuperSignal West Pico Chemiluminescent Substrates from Bio-Rad ChemiDoc MP (Shanghai, PRC) were used for chemiluminescence development.

2.11. Statistical Analysis. Statistical analysis was performed by analysis of variance (one-way or two-way) or unpaired Student’s t-test. Results are expressed as the mean ± standard error of the mean (SEM). Differences were considered significant at P < 0.05 (two-tailed).

3. Results

D-GalN/LPS-treated rats showed massive hepatocyte necrosis at the centrilobular zone and bridging necrosis severely disrupted the sinusoidal and lobular architecture of the liver (necroinflammatory score; control versus D-GalN/LPS versus AA-861: 0.33 ± 0.21 versus 8.50 ± 0.22 versus 3.2 ± 0.3, P < 0.01; Figure 1). Serum ALT, AST, and Tbil levels of D-GalN/LPS-treated rats were significantly elevated compared with controls 8 hr after administering D-GalN/LPS (2104.3 ± 124.3 versus 27.3 ± 1 U/L, 5384.2 ± 335.8 versus 94.2 ± 3.2 U/L, and 19.7 ± 1.3 versus 2.2 ± 0.3 μmol/L, resp., Figure 2). These liver damage markers reached peak value 24 hr after administering D-GalN/LPS (3992 ± 290.7 U/L, 10114.7 ± 1014.2 U/L, and 32.9 ± 2.0 μmol/L, resp.). 5-LO inhibitor AA-861 significantly alleviated the hepatocellular necrosis (Figure 1) and the serum aminotransferases (Figure 2). Moreover, 80 hr after D-GalN/LPS injection, 14 rats were dead, and 13/20 rats survived in the AA-861-treated group (Figure 3).

Our previous study demonstrated that expression of total 5-LO protein reached its peak value 24 hr after administration of D-GalN/LPS, while the expression of 5-LO mRNA reached the highest level 8 hr [19]. AA-861 significantly decreased intrahepatic 5-LO total protein (Figure 4(a)) (5-LO-positive cells: 12.3 ± 0.7/HPF versus 2.5 ± 0.4/HPF, P < 0.01; Figure 4(b)) 24 hr after administration of D-GalN/LPS and 5-LO mRNA expression (Figure 4(c)) compared with the ALF group (5-LO/β-actin IOD: 9.6 × 10⁻³ ± 1.9 × 10⁻⁴ versus 2.3 × 10⁻⁴ ± 1.2 × 10⁻⁵, P < 0.01) 8 hr after administration of D-GalN/LPS. In addition, 24 hr after D-GalN/LPS injection, LTB₄, one of the 5-LO products, was significantly elevated in the liver tissue compared with controls (84.1 ± 8.1 versus 355.4 ± 22.2 pg/mL, P < 0.01; Figure 4(d)), while AA-861 treatment significantly decreased LTB₄ (355.4 ± 22.2 versus 176.5 ± 18.5 pg/mL, P < 0.01; Figure 4(d)).

In parallel with 5-LO, the macrophage density, stained with the ED1 monoclonal antibody, was significantly higher 8 hr after D-GalN/LPS administration (9.2 ± 0.7 versus 45.7 ± 1.3, P < 0.01; Figure 5(b)), and inhibition of 5-LO significantly decreased the macrophage density (24.6 ± 1.0 versus 45.7 ± 1.3, P < 0.01; Figure 5(b)) in liver tissue. TNF-α, mainly produced by macrophages, was significantly increased in D-GalN/LPS-treated rats compared with controls (40.2 ± 3.8 versus 5.2 ± 0.5, P < 0.01; Figure 5(c)). AA-861 inhibited 5-LO, decreased macrophages in the liver of rats with D-GalN/LPS-induced ALF, and mitigated the increase in TNF-α concentration in the liver (40.2±3.8 versus 14.4±0.9, P < 0.01; Figure 5(c)).

Transmission electron microscopy showed that the inactivated macrophages in liver tissue had an irregular round...
Figure 4: AA-861 significantly decreased total hepatic 5-LO protein and mRNA expression in D-GalN/LPS-treated animals. (a) Representative western blot analysis of the total 5-LO protein expression in liver samples 24 hr after D-GalN/LPS treatment in animals receiving placebo or AA-861. (b) AA-861 significantly abrogated the increased number of 5-LO-positive cells in the liver from D-GalN/LPS-treated rats. Representative photomicrographs (400x) of liver sections immunostained with 5-LO antibody 24 hr after D-GalN/LPS-treated rats received placebo (left panels) or AA-861 (right panels). (c) Representative RT-PCR analysis of 5-LO mRNA expression in liver samples 8 hr after D-GalN/LPS treatment in animals receiving placebo or AA-861. (d) AA-861 significantly reduced LTB4 levels in liver from D-GalN/LPS-treated rats. Liver tissue was obtained 24 hr after D-GalN/LPS treatment from animals receiving placebo or AA-861. Samples were homogenized and extracted in C18-silica, reverse-phase cartridges, and LTB4 was determined by highly specific enzyme immunoassay. Results represent the mean ± standard error.

oval shape and small volume, the membrane surface had flat microvilli, and there were no obvious lysosomes or endoplasmic reticulum. The macrophages from the liver of rats with D-GalN/LPS-induced ALF showed a marked increase in size. Their outline was more regular and round, and the core of macrophages moved close to the membrane. The volume of chondriosomes increased significantly, and both lysosomes and ribosomal particles were seen, in addition to more microvilli and wrinkles on the cell surface. AA-861 treatment reversed the morphological changes in the macrophages, the cells were smaller, and the numbers of lysosomes and ribosomes in the cytoplasm were reduced (Figure 6).

4. Discussion

To the best of our knowledge, the present study is the first to show that macrophages play a critical role in D-GalN/LPS-induced ALF via the 5-LO pathway. It also showed that 5-LO inhibitor significantly alleviated D-GalN/LPS-induced ALF and that the mechanism of action may be related to inhibition of macrophage activation.

Peritoneal injection of D-GalN with LPS induces liver damage that closely resembles human viral hepatitis [20–22]. Thus, we chose to use this method to construct a rat model to imitate ALF caused by viral hepatitis in humans. We showed that D-GalN/LPS administration caused ALF, which
Figure 5: AA-861 significantly abrogated the increased number of ED1-positive cells in liver and increased level of TNF-α in serum from D-GalN/LPS-treated rats. (a) Representative photomicrographs (400x) of liver sections immunostained with ED1 antibody from control (upper left panel) and 8-hr D-GalN/LPS-treated rats receiving placebo (middle panel) or AA-861 (right panel). A representative number of ED1-positive cells (Kupffer cells) are denoted by arrows. In D-GalN/LPS-treated rats, ED1-positive cells were located mainly in the midzonal area surrounding the damaged perivenular area. (b) The number of ED1-positive cells per HPF in liver tissue sections from control (left bar) and D-GalN/LPS-treated animals receiving placebo (middle bar) or AA-861 (right bar) for 8 hr. (c) The level of TNF-α in serum from control (left bar) and D-GalN/LPS-treated animals receiving placebo (middle bar) or AA-861 (right bar) for 8 hr. Results are expressed as mean ± standard error.

Figure 6: AA-861 markedly inhibited the morphological changes in macrophages. Representative electron micrographs (the scale for the picture is 2μm) of liver sections from control (a) and 8 hr D-GalN/LPS-treated rats receiving placebo (b) or AA-861 (c).
was manifested as massive liver necrosis and significantly increased serum ALT, AST, and Tbil. Our previous study indicated that the 5-LO/LT pathway was involved in the initiation and progress of ALF induced by D-GalN/LPS [19].

So, in the present study, we investigated the relationship between 5-LO formation and macrophage activation. In addition, FLAP is also an integral component of the 5-LO pathway and its expression is crucial for the formation of LTs from arachidonic acid. However, the FLAP mRNA is not synthesized in macrophages specifically. Thus, we focused on 5-LO individually.

The first part of our study showed that AA-861 (a 5-LO inhibitor) alleviated the necroinflammatory damage to the liver in rats induced by D-GalN/LPS and improved the survival rate. From other researches, we selected the dose of AA-861 as 20–60 mg/kg [23, 24]. Thus, before the present study, we used the dose of 30 mg/kg and 60 mg/kg to do the previous experiment, respectively, and the results showed that a dose of 60 mg/kg was better. The present study proved that the 5-LO/LT pathway was involved in the progress of ALF induced by D-GalN/LPS. Blocking this pathway reduced the severity of the damage in ALF, which may offer us a new approach in the treatment of ALF by inhibition of this pathway in the future. The level of the main metabolite of the 5-LO pathway, LTB4, a potent chemotactic agent for leukocytes [25], was decreased. Our results also confirmed that 5-LO products, as mediators of inflammation and cell damage, play important roles in the pathogenesis of hepatocellular injury [26–30]. The protective effects of AA-861 on ALF were mediated by downregulation of 5-LO and its products.

It is well known that macrophages are one of the major cell types involved in initiating specific immune responses [31]. In ALF, macrophages take part in the process of the “first hit” and play an important role in the process of the “second hit” [32]. Some researchers have found that the expression of 5-LO in the liver is restricted to macrophages [15]. So, the second part of our study focused on the relationship between 5-LO formation and macrophage activation.

Using transmission electron microscopy, our previous study [33] showed the morphological changes in the macrophages in D-GalN/LPS-induced inflammation. We found that, 8 hr after D-GalN/LPS injection, the microstructural changes in the macrophages were obvious. The phagocytic and secretion activity also reached peak levels. The expression of 5-LO mRNA in liver tissue also reached a peak 8 hr after administration of D-GalN/LPS; therefore, we assumed that the synthesis of 5-LO is related to macrophage activation.

To further evaluate the potential relationship between synthesis of 5-LO and macrophage activation in the progression of D-GalN/LPS-induced ALF, we took AA-861 and found that it inhibited 5-LO formation in partially depleted ED1-positive cells (macrophages). The large increase in the number of ED1-positive cells reflected macrophage activation; therefore, we concluded that blocking the activity of 5-LO impeded macrophage activation. In addition, the prevention of hepatic necroinflammation may be associated with depletion of macrophages, which are increased in response to D-GalN/LPS injection. Some studies have demonstrated that macrophage depletion can alleviate the inflammatory response, such as endotoxin-induced lung inflammation [34] and CCl4 -induced liver injury [14]. Our results are in line with other studies in other organisms.

In addition, the anti-inflammatory effect of AA-861 on D-GalN/LPS-induced ALF in rats was also mediated through inhibition of TNF-α, which is mainly produced by macrophages and considered to be one of the main cytokines involved in hepatocellular damage [35]. Moreover, 5-LO inhibition changed the microstructure of the macrophages, which included the size of macrophages and the number of lysosomes and ribosomes in the cytoplasm. All of these findings implied that blocking the activity of 5-LO downregulated macrophage proliferation and inhibited macrophages’ function.

In conclusion, 5-LO inhibition decreased the density of macrophages and proinflammatory cytokines and alleviated D-GalN/LPS-induced liver damage. These data may help us design further studies in the treatment of ALF via inhibition of macrophage activation in the future.

Conflict of Interests
The authors declare that they have no conflict of interests.

Authors’ Contribution
Lu Li and Yi-Rong Liu contributed equally to this work. Min Qi and Yu Chen also contributed equally to this work.

Acknowledgments
This work is supported by National Science and Technology Key Project on “Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention, and Treatment” (2012ZX10002004-006, 2012ZX10004904-003-001, and 2013ZX10002002-006-001), Beijing Municipal Science and Technology Program (Z131100004613030), and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XM201308).

References
[1] W. M. Lee, R. H. Squires Jr., S. L. Nyberg, E. Doo, and J. H. Hoofnagle, "Acute liver failure: summary of a workshop," Hepatology, vol. 47, no. 4, pp. 1401–1415, 2008.
[2] R. T. Stravitz and D. J. Kramer, “Management of acute liver failure,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 9, pp. 542–553, 2009.
[3] M. Grodzicki, M. Kotulski, D. Leonowicz, K. Zieniewicz, and M. Krawczyk, “Results of treatment of acute liver failure patients with use of the prometheus FPSA system,” Transplantation Proceedings, vol. 41, no. 8, pp. 3079–3081, 2009.
[4] R. Marudanayagam, V. Shanmugan, B. Gunson et al., “Aetiology and outcome of acute liver failure,” HPB, vol. 11, no. 5, pp. 429–434, 2009.
[5] A. Hiramatsu, S. Takahashi, H. Aikata et al., “Etiology and outcome of acute liver failure: retrospective analysis of 50
patients treated at a single center," *Journal of Gastroenterology and Hepatology*, vol. 23, no. 8, pp. 1216–1222, 2008.

[6] A. Canbay, C. Jochum, L. P. Bechmann et al., "Acute liver failure in a metropolitan area in Germany: a retrospective study (2002–2008)," *Zeitschrift für Gastroenterologie*, vol. 47, no. 9, pp. 807–813, 2009.

[7] M. Akdogan, C. Camci, A. Gurakar et al., "The effect of total plasma exchange on fulminant hepatic failure," *Journal of Clinical Apheresis*, vol. 21, no. 2, pp. 96–99, 2006.

[8] A. Davenport, E. J. Will, and A. M. Davison, "Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure," *Kidney International*, no. 41, pp. S245–S251, 1993.

[9] S. Sato, K. Suzuki, Y. Takikawa, R. Endo, and M. Omata, "Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey," *Hepatology Research*, vol. 30, no. 3, pp. 155–161, 2004.

[10] H. Sekido, K. Matsuo, K. Takeda et al., "Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure," *Transplantation Proceedings*, vol. 36, no. 8, pp. 2355–2365, 2004.

[11] A. Matsui, S. Mochida, A. Ohno, S. Nagoshi, T. Hirose, and K. Fujiwara, "Plasma osteopontin levels in patients with fulminant hepatitis," *Hepatology Research*, vol. 29, no. 4, pp. 202–206, 2004.

[12] A. Hiraoka, N. Horiike, S. M. F. Akbar, K. Michitaka, T. Matsuyama, and M. Onji, "Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure," *Journal of Gastroenterology*, vol. 40, no. 1, pp. 52–56, 2005.

[13] H. J. Möller, H. Gronbaek, F. V. Schiodt et al., "Soluble CD163 from activated macrophages predicts mortality in acute liver failure," *Journal of Hepatology*, vol. 47, no. 5, pp. 671–676, 2007.

[14] E. Titos, J. Clària, A. Planagumà et al., "Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells," *Journal of Leukocyte Biology*, vol. 78, no. 4, pp. 871–878, 2005.

[15] E. Titos, J. Clària, A. Planagumà et al., "Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis," *The FASEB Journal*, vol. 17, no. 12, pp. 1745–1747, 2003.

[16] S. Ito, Y. Ito, H. Katagiri et al., "Leukotriene b 4 receptor pathway is involved in hepatic microcirculatory dysfunction elicited by endotoxin," *Shock*, vol. 30, no. 1, pp. 87–91, 2008.

[17] J. Yamate, D. Kumagai, K. Tsujino et al., "Macrophage populations and apoptotic cells in the liver before spontaneous hepatitis in Long-Evans Cinnamon (LEC) rats," *Journal of Comparative Pathology*, vol. 120, no. 4, pp. 333–346, 1999.

[18] J. W. Woods, J. F. Evans, D. Ethier et al., "5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes," *Journal of Experimental Medicine*, vol. 178, no. 6, pp. 1935–1946, 1993.

[19] L. Lu, M. Chunhua, C. Yu et al., "The expression and the role of 5-lipoxygenase in rats of acute liver failure," *Beijing Medical Infection and Communication Research*, vol. 35, pp. 1007–1010, 2013.

[20] H. Taniguchi, E. Yomota, K. Nogi, and Y. Onoda, "Effects of anti-ulcer agents on ethanol-induced gastric mucosal lesions in D-galactosamine-induced hepatitis rats," *Arzneimittel-Forschung*, vol. 52, no. 8, pp. 600–604, 2002.

[21] K. Decker and D. Keppler, "Galactosamine induced liver injury," *Progress in Liver Diseases*, vol. 4, pp. 183–199, 1972.

[22] Y. Konishi, H. Shinozuka, and J. L. Farber, "The inhibition of rat liver nuclear ribonucleic acid synthesis by galactosamine and its reversal by uridine," *Laboratory Investigation*, vol. 30, no. 6, pp. 751–756, 1974.

[23] M. Urade, R. Izumi, and H. Kitagawa, "Inhibition of 5-lipoxygenase promotes the regeneration of the liver after partial hepatectomy in normal and icteric rats," *Hepatology*, vol. 23, no. 3, pp. 544–548, 1996.

[24] R. Durmaz, E. Kasapoglu, M. Vural et al., "AA-861 appears to suppress leukocyte infiltration induced by traumatic brain injury in rats," *Neurosciences*, vol. 13, no. 3, pp. 217–226, 2008.

[25] C. D. Funk, "Prostaglandins and leukotrienes: advances in eicosanoid biology," *Science*, no. 5548, pp. 1871–1875, 2001.

[26] R. Farzanefar and K. Moore, "Cysteinyl-leukotrienes and the liver," *Prostaglandins and Other Lipid Mediators*, vol. 72, no. 1–2, pp. 35–50, 2003.

[27] D. Keppler, M. Huber, and T. Baumert, "Leukotrienes as mediators in diseases of the liver," *Seminars in Liver Disease*, vol. 8, no. 4, pp. 357–366, 1988.

[28] D. Keppler, R. Lesch, W. Reutter, and K. Decker, "Experimental hepatitis induced by d-galactosamine," *Experimental and Molecular Pathology*, vol. 9, no. 2, pp. 279–290, 1968.

[29] N. Kawada, N. Úeda, Y. Mizoguchi et al., "Increased 5-lipoxygenase activity in massive hepatic cell necrosis in the rat correlates with neutrophil infiltration," *Hepatology*, vol. 16, no. 2, pp. 462–468, 1992.

[30] K. Decker, "Eicosanoids, signal molecules of liver cells," *Seminars in Liver Disease*, vol. 5, no. 2, pp. 175–190, 1985.

[31] D. L. Laskin, "Macrophages and inflammatory mediators in chemical toxicity: a battle of forces," *Chemical Research in Toxicology*, vol. 22, no. 8, pp. 1376–1385, 2009.

[32] K. Kotoh, M. Kato, and M. Enjoji, "A new treatment strategy for acute liver failure," *World Journal of Hepatology*, vol. 2, no. 11, pp. 395–400, 2010.

[33] L. Lu, G. Yuan, C. Yu et al., "The morphological changes and the role of macrophages in rats of acute liver failure," *Chinese Hepatology*, vol. 18, pp. 597–600, 2013.

[34] M. A. Koay, X. Gao, M. K. Washington et al., "Macrophages are necessary for maximal nuclear factor-κB activation in response to endotoxin," *American Journal of Respiratory Cell and Molecular Biology*, vol. 26, no. 5, pp. 572–578, 2002.

[35] K. Matsumaru, C. Ji, and N. Kaplowitz, "Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes," *Hepatology*, vol. 37, no. 6, pp. 1425–1434, 2003.